Oculis to Present a Late-Breaking Abstract at Euretina on Phase 3 Stage 1 DIAMOND Trial Results for Diabetic Macular Edema
Oculis announced that the positive readout from Stage 1 of its phase 3 DIAMOND trial of OCS-01 in patients with diabetic macular edema (DME) will be presented as a late-breaking abstract at the 23rd Euretina Congress, taking place October 5-8, 2023 in Amsterdam, the Netherlands.
23rd Euretina Congress
Session: | Landmarks and Late Breakings session |
Presenter: | Ramin Tadayoni, M.D., Ph.D. |
Title: | A 12-week Phase 2/3 Double-masked, Randomized, Multicenter Study of OCS-01 OPTIREACH® Technology Topical Dexamethasone Eye Drops in Subjects with Diabetic Macular Edema (DME): Efficacy and Safety Findings |
Presentation time: | Friday, October 6, 2023, at 12:15 pm CEST |
Location: | RAI Amsterdam |
OCS-01 is Oculis’ lead product candidate and the first investigational eye drop for both front and back of the eye indications, with positive results in Stage 1 of the phase 3 DIAMOND trial for diabetic macular edema (DME) announced in May 2023, and positive phase 3 OPTIMIZE trial results for inflammation and pain following cataract surgery announced in August 2023. The investigator-initiated LEOPARD study evaluating OCS-01 for the treatment of cystoid macular edema (CME) enrolled its first patient in August 2023.
Leveraging Oculis’ proprietary Optireach technology, OCS-01 is a novel, high concentration (15 mg/ml), topical formulation of dexamethasone. It is developed to reach the retina via an eye drop, a route of administration that is differentiated from currently available therapies, that are all invasive such as ocular implants or intravitreal injections to deliver the medication to the retina. If approved, OCS-01 has the potential to become the first topical preservative-free eye drop for the treatment of DME, the leading cause of vision loss and legal blindness in patients with diabetes.